FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034786948> ?p ?o ?g. }

• W2034786948 endingPage "637" @default.
• W2034786948 startingPage "624" @default.
• W2034786948 abstract "PurposeTo evaluate the role of endovascular therapy in the management of infrainguinal arterial chronic total occlusions (CTOs). MethodsData on all patients with CTOs treated at a single center from 2004 to 2010 were extracted from a prospectively maintained database for retrospective analysis. Patient demographics, angiographic studies, noninvasive vascular test results, and clinical outcomes were evaluated. In this time frame, 481 patients (283 men; mean age 71.7±11.5 years, range 52–85) with claudication (n=177) or critical limb ischemia (CLI, n=304) were treated for 688 CTOs. Lesions were segregated according to location [SFA (n=193), popliteal (n=67), tibial (n=217), and multilevel (n=211)] and analyzed based on treatment mode (angioplasty, angioplasty with stenting, or atherectomy) and clinical indication. Primary patency, assisted primary patency, and secondary patency, as well as limb salvage rates for CLI patients, were calculated. ResultsAt 2 years in claudicants with CTOs confined to the SFA, primary patency ranged from 44% to 58% and secondary patency to 92% depending on treatment type; there were no significant differences among the treatments. However, in CLI patients with SFA CTOs, atherectomy produced better outcomes at 2 years (p=0.002 for primary and p=0.012 for secondary patency) than angioplasty alone. The limb salvage rates ranged from 73% to 91% (no differences among treatment types). In diabetics, CTOs treated with angioplasty and stent had improved secondary patency rates over angioplasty alone. ConclusionThe endovascular management of CTO results in reasonable primary patency; moreover, secondary patency at 2 years is excellent. Endovascular therapy should be the first-line option for many patients with peripheral artery disease, including those with CLI, claudicants with poor bypass conduit, or patients at high medical risk for surgery. The presence of CTOs does not appear to change these recommendations. Although multiple reinterventions may be required, endovascular therapies can be considered a primary therapy for many patients with CTO." @default.
• W2034786948 created "2016-06-24" @default.
• W2034786948 creator A5003195041 @default.
• W2034786948 creator A5025284856 @default.
• W2034786948 creator A5043992995 @default.
• W2034786948 creator A5047892382 @default.
• W2034786948 creator A5057112340 @default.
• W2034786948 creator A5057610160 @default.
• W2034786948 creator A5065819055 @default.
• W2034786948 creator A5069210561 @default.
• W2034786948 creator A5089616237 @default.
• W2034786948 date "2011-10-01" @default.
• W2034786948 modified "2023-10-17" @default.
• W2034786948 title "Endovascular Management as First Therapy for Chronic Total Occlusion of the Lower Extremity Arteries:<b>Comparison of Balloon Angioplasty, Stenting, and Directional Atherectomy</b>" @default.
• W2034786948 cites W1977348562 @default.
• W2034786948 cites W1977767021 @default.
• W2034786948 cites W1987857698 @default.
• W2034786948 cites W1988338662 @default.
• W2034786948 cites W2000382382 @default.
• W2034786948 cites W2001846115 @default.
• W2034786948 cites W2018940269 @default.
• W2034786948 cites W2033199068 @default.
• W2034786948 cites W2049813945 @default.
• W2034786948 cites W2051232127 @default.
• W2034786948 cites W2053044515 @default.
• W2034786948 cites W2062321446 @default.
• W2034786948 cites W2064909473 @default.
• W2034786948 cites W2068207086 @default.
• W2034786948 cites W2071141861 @default.
• W2034786948 cites W2072657412 @default.
• W2034786948 cites W2077105829 @default.
• W2034786948 cites W2078937055 @default.
• W2034786948 cites W2081439913 @default.
• W2034786948 cites W2083054238 @default.
• W2034786948 cites W2097934731 @default.
• W2034786948 cites W2123536255 @default.
• W2034786948 cites W2144985796 @default.
• W2034786948 cites W2156008429 @default.
• W2034786948 cites W4256448373 @default.
• W2034786948 doi "https://doi.org/10.1583/11-3539.1" @default.
• W2034786948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21992631" @default.
• W2034786948 hasPublicationYear "2011" @default.
• W2034786948 type Work @default.
• W2034786948 sameAs 2034786948 @default.
• W2034786948 citedByCount "63" @default.
• W2034786948 countsByYear W20347869482012 @default.
• W2034786948 countsByYear W20347869482013 @default.
• W2034786948 countsByYear W20347869482014 @default.
• W2034786948 countsByYear W20347869482015 @default.
• W2034786948 countsByYear W20347869482016 @default.
• W2034786948 countsByYear W20347869482017 @default.
• W2034786948 countsByYear W20347869482018 @default.
• W2034786948 countsByYear W20347869482019 @default.
• W2034786948 countsByYear W20347869482020 @default.
• W2034786948 countsByYear W20347869482021 @default.
• W2034786948 countsByYear W20347869482022 @default.
• W2034786948 countsByYear W20347869482023 @default.
• W2034786948 crossrefType "journal-article" @default.
• W2034786948 hasAuthorship W2034786948A5003195041 @default.
• W2034786948 hasAuthorship W2034786948A5025284856 @default.
• W2034786948 hasAuthorship W2034786948A5043992995 @default.
• W2034786948 hasAuthorship W2034786948A5047892382 @default.
• W2034786948 hasAuthorship W2034786948A5057112340 @default.
• W2034786948 hasAuthorship W2034786948A5057610160 @default.
• W2034786948 hasAuthorship W2034786948A5065819055 @default.
• W2034786948 hasAuthorship W2034786948A5069210561 @default.
• W2034786948 hasAuthorship W2034786948A5089616237 @default.
• W2034786948 hasConcept C126838900 @default.
• W2034786948 hasConcept C139059822 @default.
• W2034786948 hasConcept C141071460 @default.
• W2034786948 hasConcept C167135981 @default.
• W2034786948 hasConcept C2776268601 @default.
• W2034786948 hasConcept C2777209855 @default.
• W2034786948 hasConcept C2777303625 @default.
• W2034786948 hasConcept C2777466421 @default.
• W2034786948 hasConcept C2778283817 @default.
• W2034786948 hasConcept C2778583881 @default.
• W2034786948 hasConcept C2778963770 @default.
• W2034786948 hasConcept C2780326628 @default.
• W2034786948 hasConcept C2781099653 @default.
• W2034786948 hasConcept C3018348675 @default.
• W2034786948 hasConcept C71924100 @default.
• W2034786948 hasConceptScore W2034786948C126838900 @default.
• W2034786948 hasConceptScore W2034786948C139059822 @default.
• W2034786948 hasConceptScore W2034786948C141071460 @default.
• W2034786948 hasConceptScore W2034786948C167135981 @default.
• W2034786948 hasConceptScore W2034786948C2776268601 @default.
• W2034786948 hasConceptScore W2034786948C2777209855 @default.
• W2034786948 hasConceptScore W2034786948C2777303625 @default.
• W2034786948 hasConceptScore W2034786948C2777466421 @default.
• W2034786948 hasConceptScore W2034786948C2778283817 @default.
• W2034786948 hasConceptScore W2034786948C2778583881 @default.
• W2034786948 hasConceptScore W2034786948C2778963770 @default.
• W2034786948 hasConceptScore W2034786948C2780326628 @default.
• W2034786948 hasConceptScore W2034786948C2781099653 @default.
• W2034786948 hasConceptScore W2034786948C3018348675 @default.
• W2034786948 hasConceptScore W2034786948C71924100 @default.
• W2034786948 hasIssue "5" @default.

• next